Overview

Drugs for Schistosomiasis Market is forecasted to value over CAGR of 5.6% from the forecast period 2022-2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Drugs for Schistosomiasis Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Drugs for Schistosomiasis Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Drugs for Schistosomiasis Market are :

•    Shin Poong Pharma.Co., Ltd.
•    Merck & Co., Inc.
•    Bayer AG
•    Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
•    CBC Pharma
•    Taj Pharmaceuticals Ltd.
•    V.H. Bhagat Pharmaceuticals Pvt. Ltd.
•    VHB Life Science Inc.
•    Samarth Pharma Pvt. Ltd.
•    Shreeji Pharma International
(Note: The list of the major players will be updated with the latest market scenario and trends)

Drugs for Schistosomiasis Market Segmentation:

By Site

• Intestinal
• Urogenital

By Species Type

• Schistosoma mansoni
• Schistosoma japonicum
• Schistosoma mekongi
• Schistosoma guineensis
• Schistosoma haematobium

By Drug Type

• Praziquantel
• Metrifonate
• Biltricide
• Oxamniquine
• Others

By Region

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Drugs for Schistosomiasis Market by Site, by Species Type, by Drug Type and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Latin America, Europe, Asia Pacific and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1. Objectives of the Study 
           1.2. Market Definition 
           1.3. Market Scope 
                   1.3.1. Years Considered for the Study
                   1.3.2. Market Covered
           1.4. Currency 
           1.5. Limitations 
           1.6. Stakeholders 
 2.  Research Methodology 
           2.1. Research Data 
                   2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                   2.1.2. Primary Data
                            2.1.2.1. Key Data from Primary Sources
           2.2. Market Size Estimation 
           2.3. Market Breakdown and Data Triangulation 
           2.4. Assumptions for the Study  
3. Executive Summary
           3.1. Market Outlook
           3.2. Segment Outlook
           3.3. Competitive Insights
4. Global Drugs for Schistosomiasis Market Variables, Trends & Scope
           4.1. Market Lineage Outlook
           4.2. Penetration and Growth Prospect Mapping
           4.3. Industry Value Chain Analysis
           4.4. Cost Analysis Breakdown
           4.5. Technology Overview
           4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Drugs for Schistosomiasis Market Overview
           5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                             5.1.1.1. Increasing focus of Drugs for Schistosomiasis Companies on Brand Protection
                             5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                             5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                             5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Drugs for Schistosomiasis Market Analysis Tools
           6.1. Industry Analysis - Porter’s
                   6.1.1. Supplier Power
                   6.1.2. Buyer Power
                   6.1.3. Substitution Threat
                   6.1.4. Threat from New Entrants
                   6.1.5. Competitive Rivalry
           6.2. Pestel Analysis
                   6.2.1. Political Landscape
                   6.2.2. Environmental Landscape
                   6.2.3. Social Landscape
                   6.2.4. Technology Landscape
                   6.2.5. Legal Landscape
           6.3. Major Deals And Strategic Alliances Analysis
                   6.3.1. Joint Ventures
                   6.3.2. Mergers and Acquisitions
                   6.3.3. Licensing and Partnership
                   6.3.4. Technology Collaborations
                   6.3.5. Strategic Divestments
           6.4. Market Entry Strategies
           6.5. Case Studies
7. Global Drugs for Schistosomiasis Market, By Site Historical Analysis and Forecast 2022-2028 (USD Million)
           7.1 Intestinal
           7.2 Urogenital
8. Global Drugs for Schistosomiasis Market, By Species Type Historical Analysis and Forecast 2022-2028 (USD Million)
           8.1. Schistosoma mansoni
           8.2. Schistosoma japonicum
           8.3. Schistosoma mekongi
           8.4. Schistosoma guineensis
           8.5. Schistosoma haematobium
9. Global Drugs for Schistosomiasis Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)
           9.1. Praziquantel
           9.2. Metrifonate
           9.3. Biltricide
           9.4. Oxamniquine
           9.5. Others
10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     10.2.1. U.S.A
                     10.2.2. Canada
                     10.2.3. Mexico
           10.3. Market Size (USD Million) Forecast for North America 2022-2028 
11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     11.3.1. Brazil
                     11.3.2. Venezuela
                     11.3.3. Argentina
                     11.3.4. Rest of Latin America
           11.4. Market Size (USD Million) Forecast for Latin America 2022-2028  
12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     12.2.1. Germany
                     12.2.2. U.K
                     12.2.3. France
                     12.2.4. Italy
                     12.2.5. Spain
                     12.2.6. Russia
                     12.2.7. Poland
                     12.2.8. Switzerland
                     12.2.9. Rest of Western Europe
           12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           13.1. Introduction
           13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     13.2.1. Japan
                     13.2.2. China
                     13.2.3. Singapore
                     13.2.4. India
                     13.2.5. Australia and New Zealand
                     13.2.6. ASEAN
                     13.2.7. South Korea
                     13.2.8. Taiwan
                     13.2.9. Rest of Asia Pacific
           13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           14.1. Introduction
           14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     14.2.1. GCC
                     14.2.2. Israel
                     14.2.3. South Africa
                     14.2.4. Rest of MEA
           14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
           15.1. Shin Poong Pharma.Co., Ltd.
                     15.1.1. Company Overview
                     15.1.2. Product Portfolio
                     15.1.3. SWOT Analysis
                     15.1.4. Financial Overview
                     15.1.5. Strategic Overview
           15.2. Merck & Co. , Inc
                     15.2.1. Company Overview
                     15.2.2. Product Portfolio
                     15.2.3. SWOT Analysis
                     15.2.4. Financial Overview
                     15.2.5. Strategic Overview
           15.3. Bayer AG
                     15.3.1. Company Overview
                     15.3.2. Product Portfolio
                     15.3.3. SWOT Analysis
                     15.3.4. Financial Overview
                     15.3.5. Strategic Overview
           15.4. Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
                     15.4.1. Company Overview
                     15.4.2. Product Portfolio
                     15.4.3. SWOT Analysis
                     15.4.4. Financial Overview
                     15.4.5. Strategic Overview
           15.5 CBC Pharma
                     15.5.1. Company Overview
                     15.5.2. Product Portfolio
                     15.5.3. SWOT Analysis
                     15.5.4. Financial Overview
                     15.5.5. Strategic Overview
           15.6 Taj Pharmaceuticals Ltd.
                     15.6.1. Company Overview
                     15.6.2. Product Portfolio
                     15.6.3. SWOT Analysis
                     15.6.4. Financial Overview
                     15.6.5. Strategic Overview
           15.7. V.H. Bhagat Pharmaceuticals Pvt. Ltd.
                     15.7.1. Company Overview
                     15.7.2. Product Portfolio
                     15.7.3. SWOT Analysis
                     15.7.4. Financial Overview
                     15.7.5. Strategic Overview
           15.8. VHB Life Science Inc.
                     15.8.1. Company Overview
                     15.8.2. Product Portfolio
                     15.8.3. SWOT Analysis
                     15.8.4. Financial Overview
                     15.8.5. Strategic Overview
           15.9. Samarth Pharma Pvt. Ltd.
                     15.9.1. Company Overview
                     15.9.2. Product Portfolio
                     15.9.3. SWOT Analysis
                     15.9.4. Financial Overview
                     15.9.5. Strategic Overview
           15.10. Shreeji Pharma International
                     15.10.1. Company Overview
                     15.10.2. Product Portfolio
                     15.10.3. SWOT Analysis
                     15.10.4. Financial Overview
                     15.10.5. Strategic Overview
16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations
17. FutureWise SME Key Takeaway Points for Client

Tables

Figures